HEXAXIM

Indications

• Type 2 diabetes mellitus
• Insulin resistance
• Management of hyperglycemia

Dosage

Children: Refer to the BNF for Children for appropriate dosing information, as paediatric dosing is dependent on weight, age, and indications.

Adults: Refer to specific prescribing information for dosing guidelines as they can vary based on individual patient needs and specific formulations.

Mechanism of action

Antig primarily acts by enhancing peripheral insulin sensitivity and decreasing hepatic glucose production. It facilitates the uptake of glucose by muscle and adipose tissue and reduces the amount of glucose released by the liver into the bloodstream. This action is mediated through various signaling pathways, including the activation of AMP-activated protein kinase (AMPK) and modulation of insulin receptor signaling.

Pharmacodynamics

The drug exhibits its effects through the promotion of glucose uptake in peripheral tissues, leading to a decrease in plasma glucose levels. It also has beneficial effects on lipid metabolism and may improve cardiovascular outcomes in patients with type 2 diabetes. Antig can lead to weight loss in some patients, which is an advantageous effect given the association between obesity and insulin resistance.

Pharmacokinetics

Antig is generally well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within a few hours post-administration. It has a relatively short half-life, requiring multiple doses throughout the day to maintain therapeutic levels. The drug is metabolized primarily by the liver, with excretion occurring through the kidneys. Dosage adjustments may be necessary for patients with renal impairment.

Pregnancy

The safety of this drug during pregnancy is not well established. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether this drug is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Indications

• Vaccination against infectious diseases
• Allergy testing and immunotherapy
• Monoclonal antibody production
• Transplantation to prevent organ rejection

Dosage

Children: Dosing of antigens in children also depends on the specific antigen and the clinical indication. For pediatric vaccinations, refer to the BNF for Children.

Adults: Dosing of antigens is highly variable and depends on the specific antigen and the clinical indication. For vaccine administration, refer to national immunization guidelines.

Mechanism of action

Antigens work by binding to specific receptors on the surface of immune cells, such as B cells and T cells. This binding triggers a cascade of immune responses, including the proliferation of specific immune cell populations and the production of antibodies that target the antigen. This process is crucial for the development of adaptive immunity, allowing the body to remember and respond more effectively to future encounters with the same antigen.

Pharmacodynamics

The pharmacodynamics of antigens involve the interaction with the immune system to elicit a response. The magnitude and quality of this response can vary based on several factors, including the nature of the antigen, the route of exposure, and the host's immune status. Antigens can be classified as T-cell dependent or T-cell independent, influencing the type of immune response generated.

Pharmacokinetics

Antigens are processed by antigen-presenting cells (APCs) that present peptide fragments to T cells. The pharmacokinetics of antigens can vary widely depending on their form (e.g., live attenuated, inactivated, or subunit vaccines). Generally, once introduced into the body, antigens are taken up by APCs, which then migrate to lymph nodes to activate T and B cells. The duration of immune response can be influenced by the type of antigen and the presence of adjuvants.

Pregnancy

Safety during pregnancy depends on the specific type of antigen. Consult relevant guidelines for specific antigens.

Breast-feeding

Safety during breastfeeding varies by antigen type. Consult relevant guidelines for specific antigens.

Storage

Store at controlled room temperature, away from light and moisture. Specific storage conditions may vary based on the type of antigen.

Indications

• Prevention of diphtheria through vaccination
• Treatment of diphtheria infection
• Management of respiratory obstruction due to pseudomembrane

Dosage

Children: Refer to specific

Adults: Refer to specific guidelines for the treatment of diphtheria. Antitoxin and antibiotics are typically used in treatment.

Mechanism of action

The pathogenicity of Corynebacterium diphtheriae is largely due to its production of diphtheria toxin, an A-B toxin that inhibits protein synthesis in host cells. The toxin is composed of two subunits: the A subunit, which enters the cytoplasm of the cell and catalyzes the ADP-ribosylation of elongation factor 2 (EF-2), leading to cell death, and the B subunit, which binds to the cell surface receptor, facilitating the entry of the A subunit. This results in local tissue damage and systemic effects, including myocarditis and neuropathy.

Pharmacodynamics

Diphtheria toxin exerts its effects primarily through inhibiting protein synthesis, causing cell death in susceptible tissues. The resulting necrosis can lead to the characteristic pseudomembrane formation in the throat and can affect other organs, including the heart and nervous system. The immune response to the toxin and the bacteria provides some level of protection, which is the basis for vaccination strategies.

Pharmacokinetics

The pharmacokinetics of the diphtheria toxin itself are not typically described in terms of absorption, distribution, metabolism, and excretion, as it is a potent toxin rather than a conventional drug. However, the body’s immune response to the toxin is crucial for recovery. After vaccination, the body generates antibodies against the toxin, which can neutralize its effects upon exposure to the bacterium.

Pregnancy

Diphtheria vaccination is recommended during pregnancy to protect the mother and fetus. The vaccine is inactivated and poses no risk.

Breast-feeding

Diphtheria vaccination is safe during breastfeeding. Antibodies may be transferred to the infant through breast milk.

Storage

Store in a refrigerator at 2-8 degrees Celsius. Do not freeze.

Formulations

• Diphtheria toxoid vaccine

Dosage

Children: Refer to specific clinical guidelines and BNF for Children for dosing information.

Adults: Refer to specific clinical guidelines and BNF for dosing information.

Mechanism of action

The mechanism of action for filamentous agents can vary widely but generally involves the inhibition of cell wall synthesis, disruption of cell membrane integrity, or interference with nucleic acid synthesis. For example, in the case of certain filamentous fungi, agents may target ergosterol synthesis, a key component of fungal cell membranes, leading to cell lysis and death.

Pharmacodynamics

Pharmacodynamics of filamentous agents typically includes the assessment of their effects on target microorganisms, including bactericidal or bacteriostatic activity. These agents may exhibit time-dependent or concentration-dependent killing, influencing the choice of dosing regimens. Their efficacy can be influenced by factors such as the growth phase of the microorganism, the presence of biofilms, and the ability of the agent to penetrate tissues.

Pharmacokinetics

The pharmacokinetics of filamentous agents vary based on their chemical structure and route of administration. Common parameters include absorption, distribution, metabolism, and excretion. Many filamentous agents are administered intravenously due to poor oral bioavailability. They may also have a large volume of distribution, indicating extensive tissue binding. Metabolism can occur in the liver, and renal excretion is common, necessitating dose adjustments in patients with renal impairment.

Pregnancy

Safety during pregnancy has not been established. Consult a healthcare provider.

Breast-feeding

Consult a healthcare provider before use while breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Influenza prevention
• Influenza treatment
• Vaccine development for influenza

Dosage

Children: Refer to specific treatment guidelines for paediatric influenza management based on age and clinical presentation, as haemagglutinin is not administered as a standalone drug.

Adults: Refer to specific treatment guidelines for influenza based on clinical presentation and guidelines, as haemagglutinin is not administered as a standalone drug.

Mechanism of action

Haemagglutinin functions by specifically binding to sialic acid-containing receptors on the surface of host cells. This interaction triggers endocytosis of the virus, allowing it to enter the host cell. Once inside, the virus can release its genetic material, hijacking the host's cellular machinery to replicate and produce new viral particles. The specificity of haemagglutinin for different sialic acid variants influences the infectivity and host range of the virus.

Pharmacodynamics

The pharmacodynamics of haemagglutinin are closely tied to its role in viral pathogenesis. The strength and specificity of the binding between haemagglutinin and sialic acid receptors determine the virus's ability to infect specific tissues and initiate disease. Antibodies against haemagglutinin can neutralize the virus and are a key component of the immune response, which can lead to protective immunity following infection or vaccination.

Pharmacokinetics

As a component of a virus, haemagglutinin does not have pharmacokinetic parameters like absorption, distribution, metabolism, and excretion as traditional drugs do. Instead, its activity is related to the lifecycle of the virus it is part of. The degradation and clearance of haemagglutinin are dependent on the metabolism of the viral particles by the host's immune system and cellular mechanisms.

Pregnancy

Insufficient data available on the use of haemagglutinin during pregnancy. Consult healthcare providers for advice.

Breast-feeding

Data on the excretion of haemagglutinin in breast milk is not available. Caution is advised.

Storage

Store at 2-8°C. Protect from light and moisture.

Indications

• Bacterial meningitis
• Pneumonia
• Epiglottitis
• Otitis media
• Sinusitis
• Bronchitis

Dosage

Children: Refer to specific antibiotic guidelines for pediatric dosing based on the type and severity of the infection caused by Haemophilus species.

Adults: Refer to specific antibiotic guidelines for dosing based on the type and severity of the infection caused by Haemophilus species.

Mechanism of action

H. influenzae adheres to epithelial cells via pili and other surface structures, allowing colonization of the nasopharynx. The encapsulated strains evade phagocytosis due to their polysaccharide capsule, which inhibits opsonization and complement activation. This leads to the systemic spread of the bacteria and can result in severe infections if not effectively treated.

Pharmacodynamics

H. influenzae can produce various virulence factors, including polysaccharide capsules, endotoxins, and enzymes that contribute to its pathogenicity. The bacteria can resist the effects of certain antibiotics through mechanisms such as beta-lactamase production, which hydrolyzes beta-lactam antibiotics, rendering them ineffective. The host's immune response is often inadequate to clear the infection due to the bacterium's ability to evade immune detection.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat H. influenzae infections vary based on the specific drug. Common antibiotics include ampicillin and ceftriaxone. The absorption, distribution, metabolism, and excretion depend on the antibiotic used. For example, ampicillin is well absorbed from the gastrointestinal tract, widely distributed in body tissues and fluids, and eliminated primarily via renal excretion.

Adverse effects

• Injection site reactions
• Fever
• Rash
• Irritability
• Anaphylaxis (rare)

Precautions

• Caution in patients with a history of severe allergic reactions
• Monitor for signs of anaphylaxis after administration
• Assess for underlying immunocompromised conditions

Pregnancy

Safety during pregnancy has not been established; use only if clearly needed.

Breast-feeding

Generally considered safe, but consult a healthcare provider.

Storage

Store at 2-8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Injectable suspension
• Oral tablets

Indications

• Acute viral hepatitis
• Chronic hepatitis B
• Chronic hepatitis C
• Autoimmune hepatitis
• Alcoholic hepatitis
• Non-alcoholic fatty liver disease

Dosage

Children: Paediatric dosing also varies significantly based on the specific condition and medication. As with adult dosing, it is important to refer to the BNF for Children for specific recommendations.

Adults: Dosing for adult patients varies widely depending on the specific antiviral agent used and the type of hepatitis. It is essential to refer to specific guidelines or the BNF for precise dosing.

Mechanism of action

In viral hepatitis, the viruses typically enter liver cells and replicate, leading to cellular injury and inflammation. The immune response to the infection contributes to liver damage. Antiviral therapies aim to inhibit viral replication, either by directly targeting viral enzymes or by modulating the host immune response.

Pharmacodynamics

The pharmacodynamics of antiviral agents used in hepatitis treatment involve the inhibition of viral replication, reduction of viral load, and improvement of liver function. This can lead to a decrease in serum liver enzymes (ALT and AST) and an improvement in clinical symptoms. In chronic hepatitis B and C, sustained virologic response is the goal, indicating effective viral suppression.

Pharmacokinetics

The pharmacokinetics of antiviral medications used for hepatitis can vary significantly depending on the specific drug. Generally, these agents are absorbed from the gastrointestinal tract, metabolized in the liver, and excreted through urine or feces. The half-lives of these drugs can vary, influencing dosing schedules.

Pregnancy

Consult medical guidelines as hepatitis can pose risks during pregnancy; specific management depends on the type of hepatitis.

Breast-feeding

Consult healthcare providers, as the safety of certain hepatitis medications during breastfeeding varies.

Storage

Store in a cool, dry place away from direct sunlight; specific storage conditions may vary based on the medication used.

Indications

• Prevention of influenza virus infection
• Reduction of the severity of influenza illness
• Protection for high-risk groups against influenza complications

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for paediatric patients based on age and health status.

Adults: Refer to the BNF for specific dosing recommendations for adult patients based on the type of vaccine and individual health status.

Mechanism of action

Influenza vaccines stimulate the immune system to produce antibodies against the influenza virus. When the body is exposed to the virus, these antibodies help to prevent infection or mitigate the severity of the disease. The vaccines may contain inactivated virus or live attenuated virus, depending on the formulation.

Pharmacodynamics

Upon administration of the influenza vaccine, the immune system recognizes the viral antigens and generates a specific immune response. This response includes the production of antibodies, primarily immunoglobulin G (IgG), which can neutralize the virus and prevent its replication. The response varies based on individual health status and age.

Pharmacokinetics

The pharmacokinetics of influenza vaccines vary by type. After intramuscular or subcutaneous administration, the vaccine components are absorbed into the systemic circulation, leading to the production of antibodies. Peak antibody levels typically occur within 2 to 4 weeks after vaccination. The half-life of antibodies can vary, but they generally persist for several months, providing immunity against future infections.

Interactions

• normal immunoglobulin + influenza vaccine live: Unknown (decreases efficacy)

Pregnancy

Influenza vaccination is recommended during pregnancy, especially in the second and third trimesters, as it protects both mother and fetus.

Breast-feeding

Influenza vaccination is safe during breastfeeding and provides passive immunity to the infant.

Storage

Influenza vaccines should be stored in a refrigerator at 2 to 8 degrees Celsius. Do not freeze.

Indications

• Whooping cough (pertussis)
• Prevention of pertussis in infants and young children through vaccination

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Refer to the BNF for specific dosing information.

Mechanism of action

Pertussis toxin, produced by Bordetella pertussis, acts on host cells by ADP-ribosylating a G protein, which disrupts normal signal transduction pathways. This leads to increased production of cyclic AMP, inhibiting immune responses and contributing to the characteristic symptoms of the disease.

Pharmacodynamics

The clinical manifestations of pertussis are largely due to the immune response to the toxin and the bacterium itself. The disease progresses through stages: the catarrhal stage with mild symptoms, the paroxysmal stage with intense coughing fits, and the convalescent stage where symptoms gradually improve. The severity can vary, particularly in infants and young children, who are at higher risk for complications.

Pharmacokinetics

The pharmacokinetics of Bordetella pertussis are not typically described in the same manner as pharmaceutical agents. The organism does not have a traditional pharmacokinetic profile, but it primarily colonizes the ciliated epithelial cells of the upper respiratory tract. The immune clearance of the bacteria can take several weeks, depending on the host's immune response and treatment.

Adverse effects

• Cough
• Vomiting
• Fatigue
• Apnea (especially in infants)
• Weight loss
• Paroxysms of coughing
• Encephalopathy (rare)
• Pneumonia (secondary infection)

Precautions

• Use with caution in individuals with a history of seizures
• Consider potential for severe respiratory distress, especially in infants
• Monitor for complications, particularly in young children

Pregnancy

Pertussis vaccination is recommended during pregnancy to protect the newborn, especially during outbreaks.

Breast-feeding

Vaccination during breastfeeding is safe and can provide passive immunity to the infant.

Storage

Store in a cool, dry place away from direct sunlight. Follow specific storage instructions for vaccines.

Formulations

• DTaP vaccine (Diphtheria, Tetanus, and Pertussis)
• Tdap vaccine (Tetanus, Diphtheria, and Pertussis)

Indications

• Prevention of poliomyelitis
• Vaccination in children and high-risk populations

Dosage

Children: Refer to the BNF for Children for appropriate dosing schedules and recommendations for poliovirus vaccination in children.

Adults: Refer to specific guidelines for IPV and OPV administration in adults, as vaccination schedules may vary based on age and immunization history.

Mechanism of action

Poliovirus primarily infects the motor neurons of the spinal cord and brainstem, leading to cell lysis and apoptosis. The viral replication occurs in the cytoplasm of the host cells, resulting in the release of new virions. The immune response triggered by the infection can lead to paralysis due to damage to the motor neurons.

Pharmacodynamics

The pharmacodynamics of polio vaccines involve the induction of an immune response against the poliovirus. The IPV induces serum neutralizing antibodies, while the OPV induces both serum and mucosal immunity. This immune response prevents the establishment of infection and protects against the disease.

Pharmacokinetics

Poliovirus vaccines do not have a pharmacokinetic profile in the traditional sense, as they are biological products. However, the IPV is administered intramuscularly, leading to systemic absorption and subsequent immunogenicity. The OPV is administered orally, leading to replication in the gastrointestinal tract and inducing both humoral and cellular immunity.

Contra-indications

• Severe allergic reaction to polio vaccine components
• Immunocompromised state (inactivated vaccine preferred)

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Fever
• Fatigue
• Gastrointestinal disturbances (nausea, vomiting)
• Rarely, vaccine-derived paralytic poliomyelitis

Interactions

• Live vaccines may be affected by immunosuppressive therapies
• Concurrent administration with other vaccines is generally safe but consult vaccination guidelines

Precautions

• History of allergic reactions
• Patients with a history of Guillain-Barré syndrome
• Caution in patients with neurological disorders

Pregnancy

Polio vaccination is recommended during pregnancy if the woman is at risk of exposure, as the benefits outweigh potential risks.

Breast-feeding

Polio vaccine can be administered to breastfeeding mothers without risk to the infant.

Storage

Store at 2-8°C. Do not freeze. Protect from light.

Formulations

• Inactivated poliovirus vaccine (IPV)
• Oral poliovirus vaccine (OPV)

Indications

• Diphtheria prophylaxis
• Tetanus prophylaxis
• Pertussis prophylaxis (when combined with other vaccines)

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for pediatric immunization with toxoids.

Adults: Refer to specific guidelines for each toxoid vaccine, as dosing may vary based on the type of vaccine and individual patient factors.

Mechanism of action

Toxoids work by stimulating the immune system to produce antibodies against the toxin without causing disease. When administered, the immune system recognizes the toxoid as a foreign substance and generates a specific immune response. This includes the production of immunoglobulin G (IgG) antibodies that can neutralize the active toxin if the individual is exposed to the bacteria in the future.

Pharmacodynamics

The pharmacodynamics of toxoids involve the activation of the adaptive immune response. After vaccination, dendritic cells present the antigen to T cells, which then help B cells differentiate into plasma cells that produce specific antibodies. The presence of these antibodies provides immunity against the toxin by neutralizing its effects, thereby preventing the disease associated with the original bacterial toxin.

Pharmacokinetics

Toxoids are typically administered via intramuscular or subcutaneous injection. Following administration, they are gradually taken up by antigen-presenting cells, which then process and present the toxoid to T cells. The immunogenic response can develop over several weeks. The duration of immunity can vary, necessitating booster doses to maintain adequate antibody levels over time.

Adverse effects

• Local reactions at the injection site, such as pain, swelling, or redness.
• Fever.
• Fatigue.
• Headache.
• Allergic reactions in rare cases.

Precautions

• Use with caution in individuals with a history of severe allergic reactions to a vaccine component.
• Monitor patients for allergic reactions post-vaccination.

Pregnancy

Toxoids are generally considered safe during pregnancy; however, consultation with a healthcare provider is recommended.

Breast-feeding

Toxoids are considered safe for use during breastfeeding.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Diphtheria toxoid
• Tetanus toxoid
• Pertussis toxoid

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.